LivaNova stock
LIVNNASDAQLivaNova PLC, HealthcareISIN GB00BYMT0J19
66Score 66 out of 100, Neutral
Price and trend
86 / 100
Price history
+73% in one yearThe chart shows daily closes over 11 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 23% above it.
Since August 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 67).
The price is 3.4% below its 52-week high. Largest decline in 11 years: 74% (September 2018 to April 2025).
Chart figures for advanced users
- SMA 50$79.96
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$73.92
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)67
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$52.68
- The lowest closing price of the last twelve months.
- Resistance$94.19
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- LivaNova PLC belongs to the Medical (Devices) industry (United Kingdom) and, with a market value of $5.01B, is number 29 of 90 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $1.39B (up 10.7% year on year) and a loss of $242.5M.
- For fiscal 2026, analysts expect on average revenue of $1.53B (up 10.4%) and adjusted earnings per share of $4.41 (up 13.2%).
Show more
- MEQIRI Score 66 out of 100 (Neutral): rank 204 of 714 in Healthcare, median 53.
- The P/E is 26.6 (Medical (Devices) median 29, own median of recent years 98.2).
- Our model puts fair value at $87.73, with the price 4% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $563.5M, financial debt $347.9M.Stability 56
Weaknesses
- DilutionShare count up 12% since 2020.Capital allocation 55
Its standout strengths are momentum and technical analysis, while valuation holds the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 65 to 66.
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
What lowers it
- price near its 52-week high
- stable momentum
Valuation
Valuation signal
Fairly valuedIn our model the price counts as cheap below $67.48 and expensive above $125.33 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $76.33 (cash-flow model) and $99.12 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 9.1%. At 10.1% the fair value would be $81.39, at 8.1% it would be $97.06.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (29).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 11.7% on the twelve months before. Revenue has grown strongly since 2006, at around 14% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 68%, operating 14%, net −17%. Last 12 months: net 13%.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 24 Feb 2027in 104 days
- Last reported
- 4 Nov 2026EPS reported $1.23 (expected $1.06)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $4.41+1.3%
- Revenue
- $1.53B+0.6%
- Earnings per share
- $4.71+0.6%
- Revenue
- $1.64B+0.5%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: −11.2%Revenue guidance raised (cardiopulmonary 9.5% to 10.5% versus 8.5% to 9.5%, epilepsy 7% to 8% versus 6% to 7%) and EPS raised, while free cash flow lowered to $140 to $160 million (before: $160 to $180 million).
“For the full year 2026, we now expect Cardiopulmonary revenue to grow 9.5% to 10.5%, up from 8.5% to 9.5% previously.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 5 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 3 insiders sold, $1.03M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at LivaNova
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 66
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- Shenzhen New Industries Biomedical Engineering300832.SZ $6.9B82
- SectraSECT-B.ST $6.23B79
- APT Medical688617.SS $5.91B81
- HaemoneticsHAE $5.49B71
- Integer HoldingsITGR $4.31B58
- AxoGenAXGN $3.5B46
- AmbuAMBU-B.CO $3.41B70
- TransMedics GroupTMDX $3.2B57
ETFs that hold LivaNova
Held by 17 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Healthcare Technology & Innovation UCITS ETFXMLH | 1.99% | 0.49% | €318.39M |
| iShares Healthcare Innovation UCITS ETF2B78 | 0.49% | 0.40% | €1.49B |
| iShares Ageing Population UCITS ETF2B77 | 0.43% | 0.40% | €807M |
Show 5 more
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.24% | 0.30% | €185.82M |
| Avantis Global Small Cap Value UCITS ETFAVWS | 0.21% | 0.39% | €1.47B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.17% | 0.30% | €2.17B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.17% | 0.30% | €4.22B |
| State Street SPDR S&P 400 U.S. Mid Cap UCITS ETF (Acc)SPY4 | 0.15% | 0.30% | €5.27B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 14 Nov 2025)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.